🇺🇸 FDA
Pipeline program

Trimetazidine

CRFH20180050

Approved small_molecule active

Quick answer

Trimetazidine for Coronary Heart Disease is a Approved program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Coronary Heart Disease
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials